-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
2
-
-
0028843552
-
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
-
Non-small Cell Lung Cancer Collaborative Group
-
Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311: 899-909.
-
(1995)
BMJ
, vol.311
, pp. 899-909
-
-
-
3
-
-
1342268525
-
American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
-
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
-
(2004)
J Clin Oncol
, vol.22
, pp. 330-353
-
-
Pfister, D.G.1
Johnson, D.H.2
Azzoli, C.G.3
Sause, W.4
Smith, T.J.5
Baker Jr, S.6
Olak, J.7
Stover, D.8
Strawn, J.R.9
Turrisi, A.T.10
Somerfield, M.R.11
-
4
-
-
0033619959
-
Underrepresentation of patients 65 years of age or older in cancer-treatment trials
-
Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
-
(1999)
N Engl J Med
, vol.341
, pp. 2061-2067
-
-
Hutchins, L.F.1
Unger, J.M.2
Crowley, J.J.3
Coltman Jr, C.A.4
Albain, K.S.5
-
5
-
-
2142843806
-
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
-
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15: 2452-67.
-
(1996)
EMBO J
, vol.15
, pp. 2452-2467
-
-
Pinkas-Kramarski, R.1
Soussan, L.2
Waterman, H.3
Levkowitz, G.4
Alroy, I.5
Klapper, L.6
Lavi, S.7
Seger, R.8
Ratzkin, B.J.9
Sela, M.10
Yarden, Y.11
-
6
-
-
0034600849
-
The erbB signaling network: Receptor heterodimerization in development and cancer
-
Olayioye MA, Neve RM, Lane HA, Hynes NE. The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
-
(2000)
EMBO J
, vol.19
, pp. 3159-3167
-
-
Olayioye, M.A.1
Neve, R.M.2
Lane, H.A.3
Hynes, N.E.4
-
7
-
-
27244451321
-
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent nonsmall-cell lung cancer
-
Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent nonsmall-cell lung cancer. J Clin Oncol 2005; 23:6829-37.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6829-6837
-
-
Takano, T.1
Ohe, Y.2
Sakamoto, H.3
Tsuta, K.4
Matsuno, Y.5
Tateishi, U.6
Yamamoto, S.7
Nokihara, H.8
Yamamoto, N.9
Sekine, I.10
Kunitoh, H.11
Shibata, T.12
-
8
-
-
19944433797
-
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers
-
Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1167-1173
-
-
Tokumo, M.1
Toyooka, S.2
Kiura, K.3
Shigematsu, H.4
Tomii, K.5
Aoe, M.6
Ichimura, K.7
Tsuda, T.8
Yano, M.9
Tsukuda, K.10
Tabata, M.11
Ueoka, H.12
-
9
-
-
33746789922
-
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
-
Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3340-3346
-
-
Inoue, A.1
Suzuki, T.2
Fukuhara, T.3
Maemondo, M.4
Kimura, Y.5
Morikawa, N.6
Watanabe, H.7
Saijo, Y.8
Nukiwa, T.9
-
10
-
-
54049153188
-
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
-
Wu JY, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY, Yang PC. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med 2008;178:847-53.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, pp. 847-853
-
-
Wu, J.Y.1
Yu, C.J.2
Yang, C.H.3
Wu, S.G.4
Chiu, Y.H.5
Gow, C.H.6
Chang, Y.C.7
Hsu, Y.C.8
Wei, P.F.9
Shih, J.Y.10
Yang, P.C.11
-
11
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
-
12
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
-
13
-
-
10844231985
-
Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications
-
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
-
(2004)
Cancer Res
, vol.64
, pp. 8919-8923
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
Kuwano, H.4
Takahashi, T.5
Mitsudomi, T.6
-
14
-
-
34548052247
-
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature
-
Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, Chen Z, Gonzalez KD, Sommer SS. Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 2007;28:760-70.
-
(2007)
Hum Mutat
, vol.28
, pp. 760-770
-
-
Gu, D.1
Scaringe, W.A.2
Li, K.3
Saldivar, J.S.4
Hill, K.A.5
Chen, Z.6
Gonzalez, K.D.7
Sommer, S.S.8
-
15
-
-
29144496089
-
Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy
-
Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 2006;42:17-23.
-
(2006)
Eur J Cancer
, vol.42
, pp. 17-23
-
-
Chan, S.K.1
Gullick, W.J.2
Hill, M.E.3
-
16
-
-
36448965280
-
Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
-
Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, Mavroudis D, Georgoulias V. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 2007;97:1560-6.
-
(2007)
Br J Cancer
, vol.97
, pp. 1560-1566
-
-
Pallis, A.G.1
Voutsina, A.2
Kalikaki, A.3
Souglakos, J.4
Briasoulis, E.5
Murray, S.6
Koutsopoulos, A.7
Tripaki, M.8
Stathopoulos, E.9
Mavroudis, D.10
Georgoulias, V.11
-
17
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
-
Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
-
(2003)
JAMA
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch Jr, T.J.4
Prager, D.5
Belani, C.P.6
Schiller, J.H.7
Kelly, K.8
Spiridonidis, H.9
Sandler, A.10
Albain, K.S.11
Cella, D.12
-
18
-
-
45749120442
-
Specific EGFR mutations predict treatment outcome of stage III/IV chemonaive NSCLC patients receiving first-line gefitinib monotherapy
-
Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, et al. Specific EGFR mutations predict treatment outcome of stage III/IV chemonaive NSCLC patients receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-53.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2745-2753
-
-
Yang, C.H.1
Yu, C.J.2
Shih, J.Y.3
Chang, Y.C.4
Hu, F.C.5
Tsai, M.C.6
Chen, K.Y.7
Lin, Z.Z.8
Huang, C.J.9
Shun, C.T.10
Huang, C.L.11
Bean, J.12
-
19
-
-
52049096854
-
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-smallcell lung cancer (INVITE): A randomized, phase II study
-
Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-smallcell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008;26:4253-60.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4253-4260
-
-
Crinò, L.1
Cappuzzo, F.2
Zatloukal, P.3
Reck, M.4
Pesek, M.5
Thompson, J.C.6
Ford, H.E.7
Hirsch, F.R.8
Varella-Garcia, M.9
Ghiorghiu, S.10
Duffield, E.L.11
Armour, A.A.12
-
20
-
-
58949088423
-
Lung Oncology Group in Kyushu, Japan. A phase II trial of gefitinib monotherapy in chemotherapy-naÿve patients of 75 years or older with advanced non-small cell lung cancer
-
Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y; Lung Oncology Group in Kyushu, Japan. A phase II trial of gefitinib monotherapy in chemotherapy-naÿve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:1166-71.
-
(2008)
J Thorac Oncol
, vol.3
, pp. 1166-1171
-
-
Ebi, N.1
Semba, H.2
Tokunaga, S.J.3
Takayama, K.4
Wataya, H.5
Kuraki, T.6
Yamamoto, H.7
Akamine, S.J.8
Okamoto, I.9
Nakanishi, Y.10
-
21
-
-
45149084723
-
First-line gefitinib in patients with advanced nonsmall-cell lung cancer harboring somatic EGFR mutations
-
Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, et al. First-line gefitinib in patients with advanced nonsmall-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2442-2449
-
-
Sequist, L.V.1
Martins, R.G.2
Spigel, D.3
Grunberg, S.M.4
Spira, A.5
Jänne, P.A.6
Joshi, V.A.7
McCollum, D.8
Evans, T.L.9
Muzikansky, A.10
Kuhlmann, G.L.11
Han, M.12
-
22
-
-
73449127842
-
-
Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, Jiang H, Watkins C, Armour A, Fukuoka M. Phase III, randomized, open-label, first line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) (IPASS) [Abstract LBA2]. Ann Oncol 2008;19(suppl 8):viii1.
-
Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, Jiang H, Watkins C, Armour A, Fukuoka M. Phase III, randomized, open-label, first line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) (IPASS) [Abstract LBA2]. Ann Oncol 2008;19(suppl 8):viii1.
-
-
-
-
23
-
-
15744373791
-
-
Lyon:IARC Press
-
Travis W, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon:IARC Press, 2004.
-
(2004)
Pathology and genetics of tumors of the lung, pleura, thymus and heart
-
-
Travis, W.1
Brambilla, E.2
Müller-Hermelink, H.K.3
Harris, C.C.4
-
24
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
25
-
-
31544440171
-
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
-
Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP, Yang PC. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006;118:963-9.
-
(2006)
Int J Cancer
, vol.118
, pp. 963-969
-
-
Shih, J.Y.1
Gow, C.H.2
Yu, C.J.3
Yang, C.H.4
Chang, Y.L.5
Tsai, M.F.6
Hsu, Y.C.7
Chen, K.Y.8
Su, W.P.9
Yang, P.C.10
-
26
-
-
40749142429
-
Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response
-
Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clinical Cancer Res 2008;14:162-8.
-
(2008)
Clinical Cancer Res
, vol.14
, pp. 162-168
-
-
Gow, C.H.1
Chien, C.R.2
Chang, Y.L.3
Chiu, Y.H.4
Kuo, S.H.5
Shih, J.Y.6
Chang, Y.C.7
Yu, C.J.8
Yang, C.H.9
Yang, P.C.10
-
27
-
-
58749093115
-
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
-
Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, Shih JY, Lee YC, Yang PC. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008;32:924-30.
-
(2008)
Eur Respir J
, vol.32
, pp. 924-930
-
-
Wu, S.G.1
Gow, C.H.2
Yu, C.J.3
Chang, Y.L.4
Yang, C.H.5
Hsu, Y.C.6
Shih, J.Y.7
Lee, Y.C.8
Yang, P.C.9
-
28
-
-
20244388126
-
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
-
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2513-2520
-
-
Mitsudomi, T.1
Kosaka, T.2
Endoh, H.3
Horio, Y.4
Hida, T.5
Mori, S.6
Hatooka, S.7
Shinoda, M.8
Takahashi, T.9
Yatabe, Y.10
-
29
-
-
51049116207
-
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
-
Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clinical Cancer Res 2008;14:4877-82.
-
(2008)
Clinical Cancer Res
, vol.14
, pp. 4877-4882
-
-
Wu, J.Y.1
Wu, S.G.2
Yang, C.H.3
Gow, C.H.4
Chang, Y.L.5
Yu, C.J.6
Shih, J.Y.7
Yang, P.C.8
-
30
-
-
41549125361
-
Multicenter phase II trial of gefitinib firstline therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
-
D'Addario G, Rauch D, Stupp R, Pless M, Stahel R, Mach N, Jost L, Widmer L, Tapia C, Bihl M, Mayer M, Ribi K, et al. Multicenter phase II trial of gefitinib firstline therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008;19:739-45.
-
(2008)
Ann Oncol
, vol.19
, pp. 739-745
-
-
D'Addario, G.1
Rauch, D.2
Stupp, R.3
Pless, M.4
Stahel, R.5
Mach, N.6
Jost, L.7
Widmer, L.8
Tapia, C.9
Bihl, M.10
Mayer, M.11
Ribi, K.12
-
31
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
-
(2005)
N Engl J Med
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
Jänne, P.A.4
Kocher, O.5
Meyerson, M.6
Johnson, B.E.7
Eck, M.J.8
Tenen, D.G.9
Halmos, B.10
-
32
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
-
(2007)
Science
, vol.316
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
Park, J.O.6
Lindeman, N.7
Gale, C.M.8
Zhao, X.9
Christensen, J.10
Kosaka, T.11
Holmes, A.J.12
-
33
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 20932-20937
-
-
Bean, J.1
Brennan, C.2
Shih, J.Y.3
Riely, G.4
Viale, A.5
Wang, L.6
Chitale, D.7
Motoi, N.8
Szoke, J.9
Broderick, S.10
Balak, M.11
Chang, W.C.12
-
34
-
-
48849110458
-
Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity
-
Ardavanis A, Koumna S, Fragos I, Malliou S, Kyriakou F, Mantzaris I, Scorilas A, Rigatos G. Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity. Anticancer Res 2008;28:2409-15.
-
(2008)
Anticancer Res
, vol.28
, pp. 2409-2415
-
-
Ardavanis, A.1
Koumna, S.2
Fragos, I.3
Malliou, S.4
Kyriakou, F.5
Mantzaris, I.6
Scorilas, A.7
Rigatos, G.8
-
35
-
-
56749178852
-
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment
-
Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008; 19:2039-42.
-
(2008)
Ann Oncol
, vol.19
, pp. 2039-2042
-
-
Lee, D.H.1
Kim, S.W.2
Suh, C.3
Yoon, D.H.4
Yi, E.J.5
Lee, J.S.6
-
36
-
-
34447262600
-
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
-
Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-33.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2528-2533
-
-
Cho, B.C.1
Im, C.K.2
Park, M.S.3
Kim, S.K.4
Chang, J.5
Park, J.P.6
Choi, H.J.7
Kim, Y.J.8
Shin, S.J.9
Sohn, J.H.10
Kim, H.11
Kim, J.H.12
-
37
-
-
41949119173
-
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations
-
Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008;26:1182-4.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1182-1184
-
-
Costa, D.B.1
Schumer, S.T.2
Tenen, D.G.3
Kobayashi, S.4
-
38
-
-
33947731875
-
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
-
Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7:51.
-
(2007)
BMC Cancer
, vol.7
, pp. 51
-
-
Yokouchi, H.1
Yamazaki, K.2
Kinoshita, I.3
Konishi, J.4
Asahina, H.5
Sukoh, N.6
Harada, M.7
Akie, K.8
Ogura, S.9
Ishida, T.10
Munakata, M.11
Dosaka-Akita, H.12
-
39
-
-
26444459867
-
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer
-
Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, Tanaka S, Suga T, Saito R, IshizukaT,Dobashi K,Minna JD, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005;11:6816-22.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6816-6822
-
-
Tomizawa, Y.1
Iijima, H.2
Sunaga, N.3
Sato, K.4
Takise, A.5
Otani, Y.6
Tanaka, S.7
Suga, T.8
Saito, R.9
Ishizuka, T.10
Dobashi, K.11
Minna, J.D.12
-
40
-
-
20044364933
-
EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
-
Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65.
-
(2005)
J Clin Oncol
, vol.23
, pp. 857-865
-
-
Marchetti, A.1
Martella, C.2
Felicioni, L.3
Barassi, F.4
Salvatore, S.5
Chella, A.6
Camplese, P.P.7
Iarussi, T.8
Mucilli, F.9
Mezzetti, A.10
Cuccurullo, F.11
Sacco, R.12
-
41
-
-
24944497744
-
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
-
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5900-5909
-
-
Eberhard, D.A.1
Johnson, B.E.2
Amler, L.C.3
Goddard, A.D.4
Heldens, S.L.5
Herbst, R.S.6
Ince, W.L.7
Jänne, P.A.8
Januario, T.9
Johnson, D.H.10
Klein, P.11
Miller, V.A.12
|